High-risk medications are often started for short-term clinical reasons but remain in place long after those reasons have resolved. In post-acute settings, this creates silent risk: sedation, falls, bleeding, metabolic instability, and functional decline that appear unrelated to medication decisions. This article shows how organizations embed deprescribing controls within high-risk medication management and align them with primary care and care coordination so continuation is intentional rather than accidental.
Why deprescribing fails after discharge
Deprescribing fails because no one feels authorized to stop a medication initiated elsewhere. Post-acute clinicians may hesitate to discontinue hospital-started drugs, while primary care may assume post-acute teams will manage tapering. The result is indefinite continuation without reassessment.
Oversight expectations
Expectation 1: Ongoing need must be periodically reassessed
Surveyors and payers increasingly expect evidence that high-risk medications are reviewed for continued necessity. Indefinite continuation without documented rationale is difficult to defend.
Expectation 2: Deprescribing must be planned, not abrupt
Regulators expect tapering and monitoring plans where appropriate, especially for medications associated with withdrawal or rebound risk.
Operational Example 1: Time-limited medication flags at admission
What happens in day-to-day delivery
At admission or start-of-care, high-risk medications are flagged with an expected duration or review date. The flag triggers a scheduled review discussion with the prescriber and care team.
Why the practice exists
This prevents medications from becoming “invisible” over time.
What goes wrong if absent
Medications persist by default, exposing patients to unnecessary harm.
What observable outcome it produces
Higher rates of documented review and intentional continuation or discontinuation decisions.
Operational Example 2: Structured deprescribing review meetings
What happens in day-to-day delivery
Interdisciplinary reviews focus on high-risk medications with unclear ongoing benefit, supported by pharmacist input and patient-specific risk assessment.
Why the practice exists
This creates shared accountability for deprescribing decisions.
What goes wrong if absent
Decisions are deferred indefinitely due to uncertainty or fear of responsibility.
What observable outcome it produces
Reduced medication burden, fewer adverse effects, and clearer care plans.
Operational Example 3: Deprescribing handoff to primary care
What happens in day-to-day delivery
When deprescribing is initiated or planned, a structured handoff communicates taper schedules, monitoring needs, and follow-up responsibility.
Why the practice exists
This prevents reversal or abandonment of deprescribing plans.
What goes wrong if absent
Primary care may restart discontinued medications without context.
What observable outcome it produces
Continuity of deprescribing intent and fewer medication-related reversals.
Governance focus
Organizations that govern deprescribing through audit, review cadence, and outcome tracking reduce cumulative medication harm and strengthen defensibility.